BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BIOLIFE SOLUTIONS INC (symbol: BLFS) is the issuer of record for a Form 425 filing submitted to the SEC.
BioLife Solutions, Inc. (BLFS) is the subject of a Schedule 13G reporting 2,685,520 common shares, or 5.49% of the class as beneficially owned by Glazer Capital, LLC and its managing member, Paul J. Glazer. Each reports shared voting and dispositive power over 2,685,520 shares and zero sole voting or dispositive power.
Glazer Capital serves as investment manager to the funds holding the shares. Glazer Capital Enhanced Master Fund, Ltd. is identified as having the right to receive or direct proceeds from the sale of more than 5% of BioLife’s outstanding common stock.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Marketing Officer Todd Berard had 470 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. After this tax-withholding disposition, he holds 161,823 shares of common stock directly. No transactions were reported under a Rule 10b5-1 trading plan.
BIOLIFE SOLUTIONS INC (BLFS) executive Mathew Aby J., EVP & Chief Scientific Officer, had 564 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units, at a reference price of $36.69 per share. After this tax-withholding disposition, he holds 387,269 shares of BIOLIFE SOLUTIONS INC common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Technology Officer Sean Werner had 421 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units, at a value of $36.69 per share. After this tax-withholding disposition, he holds 47,135 shares of the company’s common stock directly, and no Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) director and President and CEO Roderick De Greef reported a Form 4 transaction involving company common stock. On September 18, 2026, 2,775 shares were withheld and disposed of to satisfy his tax withholding obligations arising from the release of restricted stock units, at a price of $36.69 per share. Following this tax-withholding transaction, he held 728,196 shares of common stock directly. No transactions were reported as made under a Rule 10b5-1 trading plan.
BIOLIFE SOLUTIONS INC (BLFS) reported that its Chief Financial Officer, Troy Wichterman, had 937 shares of common stock withheld on September 18, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. After this tax-withholding disposition, he directly holds 211,286 shares of BLFS common stock.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Marketing Officer Todd Berard had 356 shares of common stock withheld on September 8, 2026 to satisfy his tax withholding obligations arising from the release of restricted stock units. The shares were withheld by the company rather than sold in the market, and Berard continues to hold 162,293 shares of BIOLIFE common stock directly after this tax-withholding disposition. No Rule 10b5-1 trading plan is reported for this transaction.
BIOLIFE SOLUTIONS INC (BLFS) reported that executive vice president and chief scientific officer Mathew Aby J. had 627 shares of common stock withheld on September 8, 2026 to satisfy tax withholding obligations arising from the release of restricted stock units. The shares were valued at $35.38 per share, and he now directly holds 387,833 shares of common stock. This was a tax-withholding disposition rather than an open-market sale, and no Rule 10b5-1 trading plan is reported.
BIOLIFE SOLUTIONS INC (BLFS) reported that Chief Financial Officer Troy Wichterman had 1,026 shares of common stock withheld on September 8, 2026 to satisfy his tax withholding obligations arising from the release of restricted stock units. The shares were valued at $35.38 per share, and he now holds 212,223 shares directly. The transaction was a tax-withholding disposition, not an open-market sale, and no Rule 10b5-1 trading plan is reported.